Oxford Immunotec Q4 Revenues Rise 5 Percent; Plans to Shut Down Babesia Assay Project

Feb 27, 2018

|

NEW YORK (360Dx) – Oxford Immunotec reported Tuesday that its fourth quarter revenues increased 5 percent year over year, driven by continued growth in both its tuberculosis and tick-borne disease testing businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Oxford Immunotec Q4 Revenues Rise 5 Percent; Plans to Shut Down Babesia Assay Project

To read the full story....

Breaking News

Strata Oncology Receives Medicare Coverage for NGS Test

Agena Bioscience Gets FDA Emergency Use Authorization for MassArray Coronavirus Test

Kantaro Biosciences, EKF Diagnostics Ink European Distribution Deal for SARS-CoV-2 Antibody Tests

Biodesix Prices $72M IPO

Maverick Therapeutics to Use Inivata's Liquid Biopsy Assay in Phase I/II Clinical Study

Qiagen Reports 26 Percent Q3 Revenue Growth; Ups Full-Year Guidance

What's Popular?

Exact Sciences to Acquire Thrive Earlier Detection for up to $2.15B; Q3 Revenues Spike 87 Percent

Ortho Clinical Diagnostics Gets CE Mark for High-Throughput SARS-CoV-2 Antigen Test

LabCorp Q3 Revenues Rise 33 Percent

FDA Reissues EUA for Broad Institute Coronavirus Test, Authorizes Immunoassay From Celltrion

Moving From Reagents Supplier to Test Developer, Meridian Bio Expands Role During COVID-19 Pandemic

Sponsorships